SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Randomized controlled trials (RCTs) have demonstrated that pioglitazone, vitamin E [21], SGLT2 inhibitors [22], and GLP-1Ra [23] improve liver function in patients with hepatic conditions such as NAFLD (MASLD), NASH (MASH), and liver fibrosis.